45 completed. 45 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 45 | Completed 45 |
Follow Bone Marrow Diseases: new trials by email Literature Review of Bone Marrow Diseases trials Research Report on Bone Marrow Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation Asciminib - Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase | Phase 4 | Completed | Novartis Pharmaceuticals | 85 | 2024-11-28 | 2026-06-08 |
| CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly Ciclosporin, Avatrombopag, Anti-Human Thymocyte Immunoglobulin, Rabbit - Aplastic Anemia | Phase 4 | Completed | Peking Union Medical College Hospital | 86 | 2023-09-15 | 2025-04-30 |
| Ropeginterferon for Treatment Free Remission Ropeginterferon - CML (Chronic Myelogenous Leukemia) | Phase 4 | Completed | Dong-Wook Kim | 65 | 2021-11-30 | 2025-08-22 |
| Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab Eculizumab, Ravulizumab - Paroxysmal Nocturnal Hemoglobinuria | Phase 4 | Completed | Alexion Pharmaceuticals, Inc. | 18 | 2021-04-14 | 2024-09-05 |
| Combination of Thrombopoietin Mimetic and Immunosuppressive Therapy in Aplastic Anaemia Combination of thrombopoietin mimetic and cyclosporin A - Aplastic Anemia | Phase 4 | Completed | Safaa AA Khaled | 66 | 2019-11-15 | 2021-09-29 |
| A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Vitamin D3, Standard Vitamin D3 Supplementation - Vitamin D Deficiency, Stem Cell Transplant Complications | Phase 4 | Completed | Phoenix Children's Hospital | 49 | 2017-11-01 | 2020-11-17 |
| Anagre Cap. in Patients With High-Risk Essential Thrombocythemia Anagre Cap. - Essential Thrombocythemia | Phase 4 | Completed | Yuhan Corporation | 70 | 2017-06-05 | 2021-07-21 |
| King's Invasive Aspergillosis Study II Posaconazole - Aplastic Anemia, Leukemia, Myeloid, Acute | Phase 4 | Completed | King's College Hospital NHS Trust | 120 | 2016-12-07 | 2020-04-02 |
| A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Dasatinib Tablets - Chronic Myelogenous Leukemia - Chronic Phase | Phase 4 | Completed | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 62 | 2016-05-10 | 2021-06-14 |
| Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. Nilotinib - Chronic Myeloid Leukemia | Phase 4 | Completed | Novartis Pharmaceuticals | 171 | 2016-02-18 | 2022-07-22 |
| The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia Thymoglobulin, Cord blood, Cyclosporine Oral Product - Severe Aplastic Anemia | Phase 4 | Completed | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 60 | 2016-01-01 | 2023-03-17 |
| A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS) Epoetin beta - Myelodysplastic Syndromes | Phase 4 | Completed | Hoffmann-La Roche | 100 | 2014-08-06 | 2020-04-24 |
| A Rollover Study to Provide Continued Treatment With Eltrombopag Eltrombopag (ELT) - Thrombocytopaenia | Phase 4 | Completed | Novartis Pharmaceuticals | 22 | 2013-10-15 | 2022-12-30 |
| Efficacy and Safety of Nilotinib in CML-CP Nilotinib - Chronic Myeloid Leukemia, Chronic Phase | Phase 4 | Completed | Seoul National University Hospital | 110 | 2013-05-06 | 2017-11-06 |
| Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study Nilotinib - Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST) | Phase 4 | Completed | Novartis Pharmaceuticals | 57 | 2013-03-29 | 2024-02-08 |
| Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator imatinib mesylate - GIST and CML | Phase 4 | Completed | Novartis Pharmaceuticals | 155 | 2013-03-26 | 2026-10-29 |
| Biological Predictive Factors of Response to ESA in Low Risk MDS Patients Epoetin Zeta - Myelodysplastic Syndromes | Phase 4 | Completed | Association pour la recherche sur les Affections Malignes en Immunologie Sanguine | 70 | 2013-01-01 | 2018-07-26 |
| Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Dasatinib - Chronic Phase Chronic Myeloid Leukemia | Phase 4 | Completed | Bristol-Myers Squibb | 39 | 2012-12-01 | 2016-11-22 |
| Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) INC424 - Primary Myelofibrosis (PMF), Post Polycythaemia Myelofibrosis (PPV MF) | Phase 4 | Completed | Novartis Pharmaceuticals | 48 | 2012-05-01 | 2015-03-03 |
| Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients Imatinib mesylate - Chronic Myeloid Leukemia | Phase 4 | Completed | University of Milano Bicocca | 112 | 2011-11-09 | 2019-12-03 |
Showing 20 of 45. Sign in to see all of them.
Myelodysplastic Syndromes (17) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (16) · Anemia, Aplastic (6) · Iron Overload (5) · Leukemia, Myeloid, Acute (5) · Leukemia (4) · Leukemia, Myeloid, Chronic-Phase (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Thrombocythemia, Essential (3) · Blast Crisis (2) · Gastrointestinal Stromal Tumors (2) · Hematologic Diseases (2) · Hemoglobinuria, Paroxysmal (2) · Lymphoma (2)
Hemic and Lymphatic Diseases (45) · Hematologic Diseases (43) · Neoplasms by Histologic Type (26) · Neoplasms (25) · Leukemia, Myeloid (24) · Leukemia (22) · Myeloproliferative Disorders (22) · Pathological Conditions, Signs and Symptoms (22) · Pathologic Processes (21) · Chronic Disease (20) · Disease Attributes (20) · Anemia (12) · Bone Marrow Failure Disorders (7) · Nutritional and Metabolic Diseases (7)
nilotinib (8) · Deferasirox (6) · Imatinib Mesylate (6) · Antilymphocyte Serum (4) · Cyclosporine (4) · Dasatinib (2) · eculizumab (2) · fludarabine (2) · posaconazole (2) · Azacitidine (1) · Bone Marrow Transplantation (1) · Busulfan (1) · Chelating Agents (1) · Cholecalciferol (1) · Cyclophosphamide (1)
Novartis Pharmaceuticals (18) · PETHEMA Foundation (3) · Alexion Pharmaceuticals, Inc. (2) · Association pour la recherche sur les Affections Malignes en Immunologie Sanguine (1) · Bristol-Myers Squibb (1) · Celgene (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Dong-Wook Kim (1) · Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hoffmann-La Roche (1) · King's College Hospital NHS Trust (1) · Memorial Sloan Kettering Cancer Center (1) · Novartis (1) · Peking Union Medical College Hospital (1)
United States (12) · China (6) · France (6) · Germany (5) · South Korea (5) · Spain (5) · United Kingdom (5) · Canada (4) · Hong Kong (3) · Hungary (3) · Israel (3) · Italy (3) · Poland (3) · Netherlands (2) · Romania (2)
Sanz Guillermo, Dr (2) · Alessandra Iurlo, MD (1) · Alexander Ngwube, MD (1) · Andreas Hochhaus, Professor, MD (1) · Arnon Nagler, MD (1) · Barry R. Meisenberg, MD (1) · Bruno Martino, MD (1) · C L Beach, PharmD (1) · Carlo Gambacorti-Passerini, MD (1) · Cervantes Francisco, Dr (1) · Chun Wang, M.D., Ph. D. (1)
PMID 19720924, PMID 20220063, PMID 20421274, PMID 21670449, PMID 22198540, PMID 23073603, PMID 25170123, PMID 26876245, PMID 26993758, PMID 27537786, PMID 27771544, PMID 29577674, PMID 30368038, PMID 30912699, PMID 33123978, PMID 33305842, PMID 33875811, PMID 35911824
2004 (1), 2009 (1), 2015 (1), 2019 (1)